ADVFN Logo ADVFN
市場データ
ニュース
投資ツール
市場
発見

Hot Features

Follow Feed

フォローフィードコミュニティでトレーダーや投資家とつながりましょう.

ライブオプションフロー

包括的なオプション データを調査し、オプション フローで高度なフィルターを使用します.

モニター

ターミナル モニターで株式と資産のウォッチリストを整理および監視します
サインイン Premium Iconプレミアム Help Menu
Bitcoin
69,037.43
-0.33%
S&P 500
5,304.72
0.70%
Dow Jones
39,069.59
0.01%
US Dollar vs Yen
156.955
0.00%
Brent Oil
81.965
0.00%
Registration Strip Icon for discussion 登録して、同じ考えを持つ投資家と議論するためのアクティブなフォーラムで相互作用するためのアクティブなフォーラムに参加してください。
登録
  1. ホーム
  2. 投資
  3. 株式
  4. アメリカ
  5. NASDAQ
  6. Vistagen Therapeutics Inc (VTGN)

  7. Vistagen Therapeutics Inc (VTGN) ニュース

VTGN

Vistagen Therapeutics (VTGN)

Vistagen Therapeutics Inc
から:
次の項目別のソート:
 Showing the most relevant articles for your search:NASDAQ:VTGN
日付受信時刻ニュースソース見出しコード企業名
2024/05/2321 : 30Business WireVistagen to Present at the 2024 American Society of Clinical Psychopharmacology (ASCP) ConferenceNASDAQ:VTGNVistagen Therapeutics Inc
2024/05/0721 : 30Business WireVistagen to Present at the 2024 RBC Capital Markets Global Healthcare ConferenceNASDAQ:VTGNVistagen Therapeutics Inc
2024/04/2521 : 30Business WireVistagen Announces Positive Results from Phase 2A Pilot Study of PH15 for Improvement of Psychomotor Impairment Caused by Mental FatigueNASDAQ:VTGNVistagen Therapeutics Inc
2024/04/0921 : 30Business WireVistagen to Present at the 2024 Anxiety and Depression Association (ADAA) ConferenceNASDAQ:VTGNVistagen Therapeutics Inc
2024/04/0121 : 30Business WireVistagen Initiates PALISADE-3 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder Following Positive Results of PALISADE-2NASDAQ:VTGNVistagen Therapeutics Inc
2024/03/1121 : 30Business WireVistagen to Present at Stifel 2024 Virtual CNS DaysNASDAQ:VTGNVistagen Therapeutics Inc
2024/03/0708 : 00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VTGNVistagen Therapeutics Inc
2024/03/0708 : 00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VTGNVistagen Therapeutics Inc
2024/03/0708 : 00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VTGNVistagen Therapeutics Inc
2024/03/0708 : 00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VTGNVistagen Therapeutics Inc
2024/03/0114 : 15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:VTGNVistagen Therapeutics Inc
2024/02/2822 : 30Business WireVistagen to Present at TD Cowen 44th Annual Health Care ConferenceNASDAQ:VTGNVistagen Therapeutics Inc
2024/02/1508 : 18Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:VTGNVistagen Therapeutics Inc
2024/02/1506 : 51Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:VTGNVistagen Therapeutics Inc
2024/02/1422 : 56Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:VTGNVistagen Therapeutics Inc
2024/02/1406 : 52Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:VTGNVistagen Therapeutics Inc
2024/02/1406 : 33Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VTGNVistagen Therapeutics Inc
2024/02/1406 : 25Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:VTGNVistagen Therapeutics Inc
2024/02/1406 : 20Business WireVistagen Reports Fiscal 2024 Third Quarter Financial Results and Provides Corporate UpdateNASDAQ:VTGNVistagen Therapeutics Inc
2024/02/1308 : 27Edgar (US Regulatory)Form SCHEDULE 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:VTGNVistagen Therapeutics Inc
2024/02/0622 : 30Business WireVistagen to Report Fiscal Year 2024 Third Quarter Financial Results and Host Corporate Update Conference Call on February 13, 2024NASDAQ:VTGNVistagen Therapeutics Inc
2024/01/0407 : 19Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VTGNVistagen Therapeutics Inc
2024/01/0407 : 17Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VTGNVistagen Therapeutics Inc
2024/01/0407 : 09Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VTGNVistagen Therapeutics Inc
2023/12/2722 : 30Business WireVistagen Receives Notice from European Patent Office of Intention to Grant Patent for AV-101 to Treat Neuropathic PainNASDAQ:VTGNVistagen Therapeutics Inc
2023/11/1006 : 44Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:VTGNVistagen Therapeutics Inc
2023/11/1006 : 42Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VTGNVistagen Therapeutics Inc
2023/11/1006 : 30Business WireVistagen Provides Corporate Update and Reports Fiscal 2024 Second Quarter Financial ResultsNASDAQ:VTGNVistagen Therapeutics Inc
2023/11/0822 : 30Business WireVistagen to Present at Stifel 2023 Healthcare ConferenceNASDAQ:VTGNVistagen Therapeutics Inc
2023/11/0722 : 30Business WireVistagen to Present Positive Fasedienol Phase 3 Data and Positive PH80 Phase 2A Data at Upcoming Scientific ConferencesNASDAQ:VTGNVistagen Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:VTGN

最近閲覧した銘柄

LSE
SU39
Newday Fmi 25s
USOTC
LRNT
Lorain Telecom (CE)
AQSE
IHYG.GB
iShares EUR High Yield C...
NASDAQ
AAYRBXX
Royal Bank of Canada Cap...
EU
H349T
H349T
COIN
REIUSD
Zerogoki Token
COIN
ICCEUR
AMEX
XAN
Pegasus Communications
USOTC
NSHGF
Nisshin (PK)
DBI
I2CB
DAXsubsector Chemicals S...
UNSW3
BULLETH
BullionFX
LSE
SH51
Citi Fun 25
COIN
QUACKUST
RichQUACK.com
ASX
SFZ
TSXV
SUVA.U
Starlight US Multi Famil...
BOV
CEBR5Q
CEB PNA
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

日本
会社情報
ビジネス
人気
アプリを入手
App Store
Google Play

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約

© 2024 ADVFN PLC - 全著作権所有